Guidelines International Network (GIN)
Powered by EBSCO

Guidelines International Network

3261 - 3270 of 3501 results found

Tratamiento quirúrgico de la obesidad mórbida (Informe nº: Osteba D-04-01)

MeSH Terms
Obesity; Morbid (C23.888.144.699.500.500); Bariatric Surgery (E02.065.062); Gastric Bypass (E02.065.062.249); Gastroplasty (E02.065.062.750)
English Title Translation
Surgical treatment of the morbid obesity
Publication Scope
management
Countries of Application
Spain
Guideline Publication Status
Published
Languages
Spanish
Authors
OSTEBA (ES)
Publication Year
2003

Traumaperäinen stressihäiriö

MeSH Terms

Anxiety Disorders (F03.080); Mental Disorders (F03)

Guideline Contact
Raija Sipilä (raija.sipila@duodecim.fi)
English Title Translation
Post-traumatic stress disorder
Publication Date
9.1.2020, partially updated 1.12.2022
Publication Scope
assessment
management
Countries of Application
Finland
Guideline Publication Status
Published
Languages
Finnish
Authors
CC (FI)
Publication Year
2020

Traumatische knieklachten (M66)

MeSH Terms
Musculoskeletal Diseases (C05); Wounds and Injuries (C26); Joint Diseases (C05.550); Knee Injuries (C26.558.554)
Guideline Contact
Jolanda Wittenberg (j.wittenberg@nhg.org)
English Title Translation
Knee trauma (NL: Traumatische knieproblemen)
Publication Scope
assessment
management
Countries of Application
Netherlands
Guideline Publication Status
Published
Languages
Dutch
English
Authors
NHG (NL)
Publication Year
2020

Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

MeSH Terms
Hematological Disorders / Hemic and Lymphatic Diseases (C15); Therapeutics (E02); Pharmacologic Actions (D27.505)
Date for Review
2001-10-14
Publication Scope
assessment
management
Guideline Publication Status
Published
Languages
English
Authors
CHEST (US)
Publication Year
2012

Treatment of Anemia in Patients with Heart Disease: A Clinical Practice Guideline From the American College of Physicians

MeSH Terms
Hematinics (D27.505.954.502.543); Injections; Intravenous (E02.319.267.082.750); Iron (D01.552.544.412); Iron (D01.268.956.287); Iron (D01.268.556.412); Anemia; Iron-Deficiency (C15.378.071.196.300); Anemia; Iron-Deficiency (C18.452.565.100); Coronary Disease (C14.907.585.250); Coronary Disease (C14.280.647.250); Erythrocyte Transfusion (E02.095.135.140.275); Exercise Tolerance (G11.427.680.270); Heart Failure (C14.280.434)
Guideline Contact
Amir Qaseem (aqaseem@acponline.org)
Publication Scope
management
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
ACP (US)
Publication Year
2013

Treatment of Hypertension in Adults Over Age 60 to Higher vs. Lower Targets: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians

MeSH Terms
Blood Pressure (G09.330.380.076); Pharmacologic Actions (D27.505); Angiotensin-Converting Enzyme Inhibitors (D27.505.519.389.745.085); Angiotensin Receptor Antagonists (D27.505.519.162); Antihypertensive Agents (D27.505.954.411.162); Calcium Channel Blockers (D27.505.954.411.192); Calcium Channel Blockers (D27.505.519.562.249); Adrenergic beta-1 Receptor Antagonists (D27.505.696.577.050.200.200.100); Adrenergic beta-1 Receptor Agonists (D27.505.696.577.050.100.200.100); Adrenergic beta-1 Receptor Antagonists (D27.505.519.625.050.200.200.100); Adrenergic beta-1 Receptor Agonists (D27.505.519.625.050.100.200.100); Adrenergic beta-2 Receptor Agonists (D27.505.519.625.050.100.200.200); Adrenergic beta-2 Receptor Antagonists (D27.505.519.625.050.200.200.200); Adrenergic beta-2 Receptor Agonists (D27.505.696.577.050.100.200.200); Adrenergic beta-2 Receptor Antagonists (D27.505.696.577.050.200.200.200); Adrenergic beta-3 Receptor Agonists (D27.505.519.625.050.100.200.300); Adrenergic beta-3 Receptor Agonists (D27.505.696.577.050.100.200.300); Adrenergic beta-3 Receptor Antagonists (D27.505.519.625.050.200.200.300); Adrenergic beta-3 Receptor Antagonists (D27.505.696.577.050.200.200.300); Hypertension (C14.907.489); Blood Pressure (E01.370.600.875.249)
Guideline Contact
Amir Qaseem (aqaseem@acponline.org)
Date for Review
17/01/2022
Publication Scope
management
treatment
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
AAFP (US)
ACP (US)
Publication Year
2017

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

MeSH Terms
Vitamin D (D04.808.812.768); Women (M01.975); Osteoporosis (C05.116.198.579); Pharmacologic Actions (D27.505); Therapeutic Uses (D27.505.954); Alendronate (D02.705.429.500.100); Peptide Hormones (D06.472.699); Peptide Hormones (D12.644.548); Teriparatide (D06.472.699.590.850); Teriparatide (D12.644.548.587.850); Calcitonin (D06.472.699.150); Calcitonin (D12.644.400.095); Calcitonin (D12.644.548.150); Calcitonin (D12.776.641.650.095); Estrogen Replacement Therapy (E02.319.452.150); Selective Estrogen Receptor Modulators (D27.505.696.399.450.360.827); Selective Estrogen Receptor Modulators (D06.347.360.827); Raloxifene (D02.455.426.559.389.150.700.900.775); Osteoporosis; Postmenopausal (C05.116.198.579.610); Calcium (D01.268.552.100); Calcium (D01.552.539.288)
Guideline Contact
Amir Qaseem (aqaseem@acponline.org)
Date for Review
2006-06-22
Publication Scope
prevention
treatment
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
ACP (US)
Publication Year
2017